Visiting Scholar - Cancer Biology

#39;Targeting ldquo;chemotherapy-tolerantrdquo; cells in patient-derived xenograft (PDX) models of poor-prognosis acute myeloid leukemia (AML)quot;.

The candidate will generate PDX models of p53-mutant AML AML. Immediately after chemotherapy (a combination of palbociclib, the EZH2 inhibitor EPZ-6438 (tazemetostat), and daunorubicin/cytarabine) she will purify quot;chemotherapy-tolerantquot; AML cells from the mouse bone marrow and perform genomic and transcriptomic analyses to identify targetable driver mutations/gene expression pathways. If such pathways are identified, she will develop therapeutic strategies to target quot;chemotherapy-tolerantquot; AML cells in mice (the immunodeficient NRG-SGM3 strain)